Stockreport

Praxis Precision to file an NDA for relutrigine in encephalopathies in 2026 [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analy [Read more]